Transgene SA (EPA:TNG)

Market Cap	81.01M
Revenue (ttm)	6.35M
Net Income (ttm)	-33.97M
Shares Out	131.93M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,704
Average Volume	26,130
Open	0.6160
Previous Close	0.6140
Day's Range	0.6140 - 0.6260
52-Week Range	0.5500 - 1.3500
Beta	0.89
RSI	42.62
Earnings Date	Sep 16, 2025

About Transgene

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastroi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1979
• Employees: 144
• Stock Exchange: Euronext Paris
• Ticker Symbol: TNG

Financial Performance

In 2024, Transgene's revenue was 6.35 million, a decrease of -19.58% compared to the previous year's 7.90 million. Losses were -33.97 million, 52.1% more than in 2023.